Hybrid-Driven Bacillus Calmette–Guérin Carrier for Targeted Immuno-Chemo Combo Therapy in Bladder Cancer
Cyborg and Bionic Systems · 01.01.2026 · 7
DOI: 10.34133/cbsystems.0492 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cyborg and Bionic Systems, online erschienen am 28.04.2026. Verfasst von Zhanxiang Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Robotics and System, Harbin Institute of Technology, Harbin 150000, China. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Key Research and Development Program, National Natural Science Foundation of China, the National Natural Science Foundation of China.
Abstract (Originalsprache)
Combination therapy is a promising approach to enhancing antitumor efficacy and overcoming multidrug resistance. Intravesical instillation of Bacillus Calmette–Guérin (BCG) combined with chemotherapy has been employed to improve bladder cancer treatment efficacy, but outcomes are often limited by high-dose drug irritation, poor patient tolerance, and insufficient targeting. To overcome these limitations, we propose a microrobot (MR)-based targeted drug delivery strategy for precise co-delivery of BCG and paclitaxel to bladder tumors, facilitating sustained drug release and minimizing off-target effects. The MRs are fabricated using a layer-by-layer assembly technique, incorporating antitumor drugs, magnetic nanoparticles, and viable BCG. Under the synergistic action of external magnetic fields and hydrogen microbubbles generated through chemical reactions, the MRs achieve targeted navigation and effective accumulation within the 3-dimensional tumor microenvironment. Subsequently, the combined chemotherapeutic and immunostimulatory effects effectively inhibit tumor progression. This approach not only minimizes off-target effects but also facilitates sustained drug release. Additionally, a wearable magnetic fixation device based on a Halbach array is employed to fixate the MRs at the targeted region, further improving drug retention and enhancing therapeutic efficacy. The experimental results demonstrate that this MR-based delivery system holds considerable potential for clinical translation into combination therapies for bladder cancer.
Autor:innen und Institutionen
- State Key Laboratory of Robotics and System, Harbin Institute of Technology, Harbin 150000, China.
- Suzhou Research Institute of HIT, Suzhou 215104, China.
- Jiangsu Key Laboratory for Design and Manufacturing of Precision Medicine Equipment, School of Mechanical Engineering, Southeast University, Nanjing 211189, China.
- School of Mechanical and Electrical Engineering, Soochow University, Suzhou 215137, China.
ORCID-Profile: Tianlong Li
Förderung
- National Key Research and Development Program
- National Natural Science Foundation of China
- the National Natural Science Foundation of China
- National Heilongjiang Providence Nature Science Foundation of China
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Zhang, Z., Wang, L., An, Z., Jiang, Y., Niu, J., Yang, L., Wang, Q., Fan, X., & Li, T. (2026). Hybrid-Driven Bacillus Calmette–Guérin Carrier for Targeted Immuno-Chemo Combo Therapy in Bladder Cancer. Cyborg and Bionic Systems, 7. https://doi.org/10.34133/cbsystems.0492
Vancouver
Zhang Z, Wang L, An Z, Jiang Y, Niu J, Yang L, et al. Hybrid-Driven Bacillus Calmette–Guérin Carrier for Targeted Immuno-Chemo Combo Therapy in Bladder Cancer. Cyborg and Bionic Systems. 2026;7. doi:10.34133/cbsystems.0492
BibTeX
@article{Zhang2026,
author = {Zhang, Zhanxiang and Wang, Lin and An, Zhongcheng and Jiang, Yuhang and Niu, Jiawen and Yang, Laishou and Wang, Qianqian and Fan, Xinjian and Li, Tianlong},
title = {Hybrid-Driven Bacillus Calmette–Guérin Carrier for Targeted Immuno-Chemo Combo Therapy in Bladder Cancer},
journal = {Cyborg and Bionic Systems},
year = {2026},
volume = {7},
doi = {10.34133/cbsystems.0492}
}
EUVIMED